[ad_1]
The use of palivizumab in infants with cystic fibrosis (CF) may not lead to long-term improvements, according to a new study published in pediatrics. Researchers used data from the Cystic Fibrosis Foundation's Patient Registry.
The registry was used to search for links between the administration of palivizumab during the first two years of life and long-term outcomes such as pulmonary function at the age of 7 years; hospitalizations attributed to pulmonary problems during the first seven years of life; and time to the first Pseudomonas aeruginosa Culture. The sample included all eligible infants born between 2008 and 2015 who were diagnosed with CF in the first six months of life.
Of the 4267 infants, 1588 received palivizumab. Mean forced expiratory volume in 1 second at 7 years was similar in those who had not received palivizumab (97.3, confidence interval [CI], 96,1-98,5) and those who received it (98,2; CI, 96,9-99,5). Similarly, the researchers found that the annual risk of hospitalization and the delay before the first positive culture P aeruginosa were about the same between the 2 groups.
The researchers concluded that long-term outcomes for infants with cystic fibrosis who had been prescribed palivizumab did not appear to be different from those of other patients. They also said the next step should be for high-risk infants. In addition, they called for the creation of concise definitions of chronic lung diseases and nutritional problems in children with cystic fibrosis.
Source link
